Newly Diagnosed Multiple Myeloma Active Not Recruiting Phase 3 Trials for Elotuzumab (DB06317)

Also known as: Newly Diagnosed Multiple Myeloma (NDMM) / Newly Diagnosed, Multiple Myeloma / Multiple Myeloma, Newly Diagnosed

IndicationStatusPhase
DBCOND0036257 (Newly Diagnosed Multiple Myeloma)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03948035Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMTreatment